Investigators Seek FREEDOM From Uncertainly Of Late-Loss Significance
This article was originally published in The Gray Sheet
Executive Summary
The ongoing FREEDOM trial will help clarify the importance of late lumen loss as a comparative measure of drug-eluting stent efficacy, according to Cardiovascular Research Foundation webcast participants